-
Overview of clinical projects of cancer cell immunotherapy: over 2000 pipelines CAR-...
Time of Update: 2021-06-23
Recently, IQVIA, a world-renowned medical industry consulting company, and the non-profit organization Cancer Research Institute (CRI) published an analyst report titled The clinical pipeline for cancer cell therapies in Nature Reviews Drug Discovery, a subsidiary of Nature, describing It shows the current global clinical research and development picture of cancer cell immunotherapy .
-
2021 EHA Voice of China Professor Zhou Daobin's team new progress: R2-MTX regimen for the treatment of newly diagnosed PCNSL
Time of Update: 2021-06-22
Abstract Number: S223 Title: Phase IB/II Study: Combination therapy of lenalidomide, rituximab, and high-dose methotrexate (R2-MTX), followed by lenalidomide maintenance treatment for newly diagnosed primary central nervous system Systematic lymphoma research method This is a multi-center, prospective phase Ib/II study (NCT04120350) .
-
The complete remission rate of refractory patients exceeds 30% CD37 targeted ADC combination Phase 2...
Time of Update: 2021-06-22
On June 14, 2021, Debiopharm announced that its CD37-targeted antibody conjugate (ADC) naratuximab emtansine, combined with rituximab (anti-CD20 antibody), is used in the treatment of relapsed/refractory (R/R) diffuse Positive results were obtained in a phase 2 clinical trial of large B-cell lymphoma (DLBCL) .
-
Best-in-class security!
Time of Update: 2021-06-22
Reddy Laboratories and Simcere Pharmaceuticals respectively, Prekin announced the targeting of BCMA CAR-T at the ASCO 2021 annual meeting The latest data of an unregistered clinical study conducted by Cell Injection in Henan Cancer Hospital.
-
2021 EHA Big Coffee Interview Professor Cao Xinxin: Interpretation of Research Progress in Light Chain Amyloidosis
Time of Update: 2021-06-22
In all previous studies of daratumumab, almost no patients in Mayo2004 phase IIIb were enrolled, so for these ultra-high-risk AL amyloidosis patients, how to choose daratumumab and which drugs should be combined for treatment , Is the current clinical problem that needs to be solved urgently .
-
EHA 2021: The latest results of clinical trials of CRISPR and Vertex for the treatment of hereditary hemoglobinopathy are positive
Time of Update: 2021-06-22
Recent popular reports from Yimaike ★ Invitation to the event 2021 Oncolytic Virus Drug Development Forum is about to open in Shanghai ★ The financing has been hundreds of millions in half a year, an
-
The prognosis of AML with other gene mutations in different IDH mutation subgroups is different
Time of Update: 2021-06-22
Based on this, some researchers retrospectively analyzed the prognosis of newly diagnosed AML patients with IDH mutation who received IC treatment based on data from three prospective clinical trials of the French Acute Leukemia Association (ALFA) .
-
2021 EHA Eltropapax shows considerable efficacy and safety in the treatment of aplastic anemia
Time of Update: 2021-06-22
Abstract S172: First-line treatment of adult SAA patients with Eltrombopag combined with cyclosporine: Results of Phase II SOAR Study Background Severe Aplastic Anemia (SAA) is a life-threatening disease of bone marrow failure characterized by pancytopenia and Decreased bone marrow cells .
-
Nature Medicine blockbuster article: The new CRISPR-Cas9 technology can realize the replacement of complete endogenous genes and successfully treat the β-thalassemia mouse model
Time of Update: 2021-06-22
▲ Image source: Nature Medicine In this study, researchers used LONZA 4D-Nucleofector to electroporate CD34+ HSPC from β-thalassaemia, and then used AAV6 as a carrier to deliver IDT’s Cas9 combined with chemically synthesized sgRNA to HSPC for processing Gene editing, while maintaining the highly homologous HBA2 gene, knock out the endogenous HBA1 gene and replace it with the full-length HBB gene .
-
CD37 ADC combined with CD20 monoclonal antibody in the treatment of DLBCL, clinical results are positive, Yi Mai Meng broke the news
Time of Update: 2021-06-22
Recent popular reports from Yimaike ★ Invitation to the event 2021 Oncolytic Virus Drug Development Forum will open in Shanghai ★ The financing has reached hundreds of millions in half a year, and th
-
Express all patients in remission, CRISPR gene editing therapy shows "cure" potential
Time of Update: 2021-06-22
Through CTX001 treatment, HbF levels can be increased, it is possible to alleviate the blood transfusion needs of TDT patients, and reduce the pain and debilitating vascular occlusive crisis of SCD patients .
-
[EHA hot spot] FcRH5/CD3 bispecific antibody Cevostamab may bring new hope to RRMM patients
Time of Update: 2021-06-22
Cevostamab Cevostamab is a humanized, IgG-based T cell binding bispecific antibody that targets FcRH5 (Fc receptor homolog 5) on the surface of myeloma cells and CD3 on the surface of T cells to form
-
Express delivery of potential "first-in-class" complement inhibitors to reach the phase 3 clinical endpoint, and submit a regulatory application this year
Time of Update: 2021-06-22
▎WuXi AppTec content team editor A few days ago, Sanofi announced that its potential "first-in-class" complement C1s protein inhibitor sutimlimab is a pivotal phase 3 clinical trial in the treatment of patients with cold agglutinin disease (CAD) It can quickly and continuously inhibit the hemolysis caused by C1 activation in CAD patients, and it can also provide clinically significant improvements in patients' hemoglobin levels and fatigue .
-
EHA hot spot: A number of phase III studies of C5 complement inhibitor Crovalimab have entered the recruitment phase, and the research and development in China is synchronized with the global
Time of Update: 2021-06-22
At the 26th European Annual Conference on Blood (EHA) this year, crovalimab announced three important research designs, including two important phase III clinical trials (COMMODORE 1, COMMODORE) 2), and a study related to the burden of PNH disease (COMMODORE BoI).
-
NSMB Xu Dong Group Reveals New Pathogenesis of Fanconi's Anemia
Time of Update: 2021-06-22
On June 10, 2021, the research group of Dongyi Xu from the School of Life Sciences, Peking University published an article Fanconi anemia proteins participate in a break-induced-replication-like pathway to counter replication stress on Nature Structural & Molecular Biology, and found that the FA pathway is essentially A break-induced replication (BIR) pathway is used to repair stagnant replication forks, and the view that sustained replication pressure is a potential endogenous cause of FA symptoms .
-
[Lymphoma Microcourse 2021EHA] EP636 First-line Treatment of Ibrutinib in Patients with Chronic Lymphocytic Leukemia: 7-year follow-up of the RESONATE-2 study
Time of Update: 2021-06-22
Today I will mainly introduce an abstract on EHA in 2021: First-line treatment of Ibrutinib in patients with chronic lymphocytic leukemia: 7-year follow-up of the RESONATE-2 study .
-
What are the important developments of innovative therapies developed around p53 targets in the past 40 years?
Time of Update: 2021-06-22
At the just-concluded 2021 American Society of Clinical Oncology (ASCO) annual meeting, the small molecule MDM2 inhibitor APG-115 from Ascent Pharmaceuticals, the new p53 targeting drug APR-246 from Aprea Therapeutics, and Boehringer Ingelheim (Boehringer Ingelheim) ) The MDM2-p53 antagonist BI 907828 and other products under development have shown their latest research progress .
-
Blood: The clonal evolution of the FLT3-ITD mutation in acute myeloid leukemia
Time of Update: 2021-06-21
In 32% of cases, no changes in FLT3-ITD mutations were observed, indicating that the resistance mechanism bypassed FLT3 inhibition or that the inhibitory activity of Mistaline was lost due to insufficient drug levelsIn conclusion, this study provides new insights into the clonal evolution and resistance mechanisms of AML patients with FLT3-ITD mutations under the treatment of Mistalin combined with intensive chemotherapy .
-
Blood: Acquired platelet GPVI receptor dysfunction suggests early sepsis!
Time of Update: 2021-06-21
Glycoprotein VI (GPVI) is a platelet immune receptor tyrosine activated motif (ITAM) receptor for collagen , which plays an important role in vascular integrity in animal models of inflammation and sepsis .
-
Blood: Gain-of-function mutations in Cxcr4 lead to out-of-control immune responses outside the follicle!
Time of Update: 2021-06-21
In summary, the results of this study indicate that Cxcr4 desensitization plays a key role in the process of B cell activation and plasma cell differentiation, and fine-tuning of Cxcr4 signal is essential to limit the intensity and duration of the immune response outside the follicle .
